Trial Profile
An Eight-Week, Randomized, Double-Blind, Parallel Group, Multicenter, Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren Administered Alone and in Combination With Ramipril in Patients With Hypertension and Diabetes Mellitus.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 May 2017
Price :
$35
*
At a glance
- Drugs Aliskiren (Primary) ; Ramipril
- Indications Essential hypertension
- Focus Pharmacogenomic; Therapeutic Use
- Sponsors Novartis
- 06 Nov 2012 Planned number of patients (846) added as reported by European Clinical Trials Database.
- 10 May 2011 New source from European Clinical Trials Database identified (EudraCT2004-001062-40) and integrated.